Wanting is not liking
Decades of work distinguishing 'wanting' from 'liking' found that animals with depleted dopamine still show normal pleasure responses to sweet tastes — they simply will not work to obtain them. The enjoyment survives; the drive to pursue it does not.
This maps closely onto how anhedonia is actually described by people experiencing it. The common report is not that things feel bad, but that nothing feels worth the effort of starting. That is a motivation signal problem, not a pleasure problem.
It also reframes what dopamine dysfunction looks like: flattened effort, difficulty initiating, and a shrinking of the range of things that seem worth doing.
Baseline versus peak
The useful mental model is a baseline with peaks above it. Behaviours that produce very large, very fast peaks — certain drugs, slot-machine-style feeds, compulsive scrolling — appear to be followed by a compensatory dip below baseline, and repeated exposure appears to drag the baseline itself down.
The consequence is that ordinary rewards stop registering. Not because they changed, but because the reference point moved.
This is the mechanistic core of what recovery communities describe as the flatness of early abstinence, and it is why the first weeks are so hard: baseline has to come back up before ordinary life feels worth anything again, and it does not do so quickly.
Where compounds fit, honestly
The peptide evidence here is thin and mostly indirect. Semax modulates dopaminergic tone in animal models. BPC-157 has a rodent literature reporting protection against dopamine-system disturbances, including in models relevant to withdrawal. Both are animal findings.
The upstream story is more defensible. Dopamine synthesis requires tyrosine, iron, and B6. It is ATP-dependent, which puts it downstream of mitochondrial function. Sleep deprivation downregulates D2 receptor availability in human imaging studies. These are not exotic interventions; they are the substrate.